Ming-thau Sheu
Affiliated Society: Chinese Taipei Society for Biomaterials
Country of Residence: Taiwan, ROC
Current Position: Professor
Biography:
I am the faculty of School of Pharmacy, College of Pharmacy, Taipei Medical University. I was appointed as the Dean of College of Pharmacy, Taipei Medical University since 2010. I graduated from School of Pharmacy, Taipei Medical College at 1977, granted M.S. degree at 1979 by Graduate Institute of Applied Chemistry, National Hsing-Hwa University, and had Ph.D. from College of Pharmacy, The Ohio State University at 1986. I have received Research Assistance Award, NSC during 1987-2001; Doctor Huang’s Scholarship Award at 1993, 1997, and 2001; Candidates for Outstanding Research Award, NSC during 2000-2003; The Copper Research Award, TMU at 2000 and The Gold Research Award, TMU at 2001. I was granted the title of International Fellow of Biomaterials Science and Engineering (FBSE), International Union of Societies for Biomaterials Science and Engineering at 2012. I have serves as the chairman of Biomaterials and Controlled Release Society of Taiwan since 2011 and as the president of CRS Taiwan Local Chapter since 2010. I served as Executive Board Member for Biomaterials and Controlled Release Society of Taiwan (2001-present); Secretary in General for Cultural Foundation of Pharmaceutical Alumni of School of Pharmacy (1990-1996); Board Member for Pharmaceutical and Biomedical Technology Development Center (1995 – 2004); Editorial Board Member for Asian J of Pharmaceutical Sciences (2007- ); Editorial Board Member for J of Experimental and Clinical Medicine, TMU (2009- ). I have published more than 149 SCI papers and 8 patents even since. Total Citation number for 145 papers is 2276 (0801/2016), H-Index=26, with 3 and 8 papers were cited more than 100 and 50 times, respectively, and the highest citation number was 149.
Areas of research interest:
I devote to research and development of Biomaterials for applications in tissue engineering and drug delivery systems. Since then, those biomaterials studied included Fibrin, Collagen, Hyaluronic acid, PRP and PRF, and Sacchachitin. HA derivatives with different ADH modifications were performed in vivo real-time imaging studies using orally administrated QDot-HA conjugates. Through understanding the biological behavior of HA derivatives and potential influences of the MW and chemical modification, the pharmacokinetic properties of HA can be tailored to regulate its biodistribution to further provide new options for targeted therapy via oral administration. The rapid clearance and elimination of HA intra-articular injection may limit its clinical usage; therefore, the improvements of longer residence time may extend the therapeutic benefit and clinical applications. We hypothesized that the combination of HA and DOX in a hydrogel might produce additive effects in OA therapy through the anti-inflammatory and analgesic effects of DOX and HA, respectively, and the in- creased viscoelasticity of the synovial fluid resulting from the high-molecular-weight hydrogel polymer. In addition, the slow release of DOX from the hydrogel polymer may sustain its therapeutic effects. We produced an injectable HA-DOX hydrogel, and evaluated its efficacy as an intra-articular treatment in a rabbit model of OA. Results revealed that the HA-DOX hydrogel, composed of a polymer of HA and DOX with zinc cations, possessed higher viscosity and viscoelasticity, and provided better chondroprotective effects than those of an HA alone. Therefore, the injectable HA-DOX hydrogel may represent a desirable DMOAD for OA therapy. Platelet-rich plasma (PRP) prepared from whole blood is an autologous product and contains high concentration of platelet growth factors. These growth factors act locally to recruit undifferentiated cells to the site of injury, to trigger mitosis in these cells, and to induce angiogenesis. Application of PRP provides the nerve with a medium enriched with platelet growth factors to improve regeneration. Over the last decade, PRP has been used to improve clinical outcomes in cardiac, plastic, periodontal surgical therapy, and intrabony defects. Some studies have demonstrated high concentration of growth factors in the PRP that may enhance the tissue repair process. The use of PRP on the crushed site has also shown promising results for nerve regeneration. However, the effects of PRP injection in corpus cavernosum in bilateral CN injury have never been investigated. The neuroprotective effect of PRP on EF in bilateral CN injury using the rat model was assessed. It was found that PRP injection in corpus cavernosum increased the number of myelinated axons and facilitated recovery of EF in bilateral CN injury rat model. The regenerative potential of PRP depends on the amount of secretory growth factors that are released on platelet
Research keywords:
Drug Delivery